TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04652700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: ISL 60 mg tablet, QM, orally for up to 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo ISL 0 mg tablets QM, orally for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to FTC/TDF
Description: Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to FTC/TAF
Description: Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
Study: NCT05949840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive Interviewing
Description: Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
Study: NCT06447480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISOtretinoin 5 MG
Description: The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended.
Study: NCT06072638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating in Absence of Hunger
Description: Researcher gives child free access to palatable foods following a satiating meal.
Study: NCT05066984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured, multidisciplinary and personalized post-ICU care
Description: Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
Study: NCT06447480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical cream
Description: Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
Study: NCT05725941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TogRite stretch Strapping
Description: it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional upper limb functional exercise training
Description: The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional upper limb functional exercise training
Description: The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
Study: NCT06143917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-child sleep intervention
Description: The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
Study: NCT05223868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study: NCT06366243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral delayed-release capsule
Study: NCT05023031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2102
Description: Tablet formulation for oral administration, single dose of NVP-2102 at Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2102-R
Description: Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
Study: NCT05071924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH Teens Original: In-person PLH programme for parents and teens by community-based workers
Description: This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators
Description: The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
Study: NCT04869241

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: surface EMG
Description: Carrying backpacks forward or backward
Study: NCT04764552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeahhh Baby Ointment
Description: The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coconut oil ointment
Description: Coconut oil ointment with a little olive oil.
Study: NCT05223868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study: NCT05647369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastic mouthwash
Description: All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
Study: NCT06298149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Island Tales
Description: All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
Study: NCT04321551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cyp 200Mg/Ml Inj (in Oil)
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
Study: NCT05112510

Intervention type: OTHER
Intervention: Observing whether developing distant metastasis or recurrence
Description: The study is a observational study and has no intervention.

Intervention type: OTHER
Intervention: Observing whether developing distant metastasis or recurrence
Description: The study is a observational study and has no intervention.
Study: NCT05478304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip LAA Exclusion System
Description: LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
Study: NCT05956041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400mg Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: 1mg/kg Intravenously
Study: NCT06431750

Intervention type: OTHER
Intervention: Secukinumab
Description: This is an observational study, there is no treatment allocation.
Study: NCT06418867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness Practice including 6 sessions with 1 hour for each
Study: NCT06370585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-229
Description: - Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.
Study: NCT06237062

Intervention type: OTHER
Intervention: erenumab
Description: This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
Study: NCT05984433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Electro auricular acupuncture
Study: NCT04735640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led teleconsultation
Description: Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
Study: NCT05500222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resmetirom
Description: Randomized 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized matching placebo
Study: NCT06370585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lagricel® Ofteno PF
Description: - Sodium hyaluronate 0.4%. Ophthalmic solution.
Study: NCT05398198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 dose and administration as per study intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3923868 will be administered.
Study: NCT06307704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound - guided Stepwise PEEP
Description: After endo-tracheal intubation; A PEEP of 4 cmH2O will be initially used till 5 min after pneumoperitoneum. Then The PEEP will be adjusted in a stepwise approach after performing bedside lung ultrasound. The PEEP will be increased by 2 cmH2O until no lung collapse is detected. Lung ultrasound will be repeated 5 min after every change in the PEEP with a maximal PEEP of 12 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ventilation Protocol
Description: Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Ventilation Protocol
Description: Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
Study: NCT04920773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guduchi Ghanvati
Description: 500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
Study: NCT05184829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selective lymph node dissection
Description: selective lymph node dissection
Study: NCT05085145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
Study: NCT06098833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Blend
Description: Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Study: NCT06441422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: Participants randomized to blood flow restriction training will complete low load resistance training exercises while the limb is occluded at 80% arterial occlusion pressure.
Study: NCT06480630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
Study: NCT05073471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patterned Sensory Enhancement (PSE)
Description: Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily.
Study: NCT06441422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No blood flow restriction training
Description: Participants randomized to no blood flow restriction training will complete low load resistance without occlusion.
Study: NCT05073471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patterned Sensory Enhancement (PSE)
Description: Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure.
Study: NCT05234671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: 12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
Study: NCT06251947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim Alfa
Description: Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Study: NCT04861181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics, Dosage of Niraparib
Description: The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
Study: NCT04503005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time Restricted Eating
Description: Effect of 16, 14 or 12 hours of daily fasting

Intervention type: OTHER
Group type: OTHER
Intervention: Time Restricted Eating
Description: Effect of 16, 14 or 12 hours of daily fasting
Study: NCT04920773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard guidelines
Description: Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
Study: NCT05013801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic facial serum Q69
Description: Cosmetic facial serum

Intervention type: DRUG
Group type: OTHER
Intervention: 2% Hydroquinone
Description: 2% Hydroquinone cream
Study: NCT06493162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow Controlled Ventilation
Description: Patients in FCV group will be ventilated with flow controlled ventilation mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volume Controlled Ventilation
Description: Patients in VCV group will be ventilated with volume controlled ventilation mode
Study: NCT04920773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard guidelines
Description: Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
Study: NCT05184829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Lymph Node Dissection
Description: Systemic Lymph Node Dissection
Study: NCT06130475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution (ORS)
Description: Participants will be administered the ORS during one of the study visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered water during one of the study visits